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Background: Trisomy 9p is an uncommon anomaly characterised by mental retardation, head and facial
abnormalities, congenital heart defects, kidney abnormalities, and skeletal malformations. Affected children may also
show growth and puberty retardation with delayed bone age. Auxological and endocrinological data are lacking
for this syndrome.
Methods: We describe three girls and one boy with 9p trisomy showing substantial growth failure, and we
evaluate the main causes of their short stature.
Results: The target height was normal in all families, ranging from 0.1 and −1.2 standard deviation scores (SDS).
The patients had a low birth-weight (from −1.2 to −2.4 SDS), birth length (from −1.1 to −3.2 SDS), and head
circumference (from −0.5 to −1.6 SDS). All patients presented with substantial growth (height) retardation at the
time of 9p trisomy diagnosis (from −3.0 to −3.8 SDS).
The growth hormone stimulation test revealed a classic growth hormone (GH) deficiency (GHD) in patients 1, 3,
and 4. In contrast, patient 2 was determined to have a GH neurosecretory dysfunction (GHNSD). The plasma
concentrations of IGF-I and IGFBP-3 were low in all patients for their ages and sexes (from −2.0 to −3.4 SDS, and
from −1.9 to −2.8 SDS, respectively).
The auxological follow-up showed that those patients who underwent rhGH treatment exhibited a very good
response to the GH therapy, whereas patients 3 and 4, whose families chose not to use rhGH treatment, did not
experience any significant catch-up growth.
Conclusions: GH deficiency appears to be a possible feature of patients with 9p trisomy syndrome. These patients,
particularly those with growth delays, should be evaluated for GH secretion.
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Trisomy 9p is the fourth most frequent chromosome
anomaly in live-born infants, after trisomies 21, 18, and
13 [1]. Since the original publication by Rethoré et al.
[2], more than 150 patients with partial or complete 9p
trisomy have been reported [1].
This disorder can occur because of a balanced chromo-
somal rearrangement between two chromosomes in one
of the parents or as the result of a spontaneous (de novo)
genetic change early in embryonic development occurring
for unknown reasons [3-5].
In this disorder, part or all of the short arm (p) of
chromosome 9 is duplicated [5]. In some cases, an extra
(trisomic) segment of the long arm (q) of chromosome 9
may also be present [5].
The signs of this disorder are unusually similar among
affected children, despite differing lengths of the dupli-
cated segment. Patients with 9p trisomy exhibit mental
retardation and characteristic head and facial abnormal-
ities, such as microcephaly with large anterior fontanel
and micrognathia, malformed protruding ears, hyperte-
lorism, deep set eyes, and down slanting palpebral
fissures [3,5]. Congenital heart defects [6,7], central ner-
vous system abnormalities [8,9], kidney abnormalities
[3,5], and skeletal malformations [10,11] are also present.
With respect to facial features, duplication of 9pter-p11
is associated with milder dysmorphia, whereas duplication
of 9p21.1-q22-32 is associated with more severe craniofa-
cial features [12].
Affected infants may also show growth retardation and
delayed bone age [5]. However, very rarely has growth
hormone (GH) deficiency (GHD) been reported [13].
Here, we studied the causes of short stature and inves-
tigated the GH insulin-like growth factor I (IGF-I) axis
in patients with 9p trisomy during the follow-up of these
patients, three of whom reached adult height.
Methods
Four Caucasian subjects with 9p trisomy syndrome (1 boy
and 3 girls, mean age at the diagnosis of 9p trisomy syn-
drome 19.5 months [range: 0.2 – 45.0]) who presented
consecutively at the Genetics and Molecular Medicine
Unit of Anna Meyer Children's University Hospital in
Florence and were brought to us for delayed growth and
development were evaluated.
A diagnosis of 9p trisomy syndrome was made for all
subjects between 1994 and 2009 based on the clinical
phenotype assessed by an experienced medical geneticist
in our hospital and was confirmed by chromosome
analysis.
All subjects underwent an extensive endocrine work-up
to rule out possible causes of growth failure that included
IGF-I, free-thyroxin (FT4), thyroid stimulating hormone
(TSH), cortisol, glucose, electrolytes, venous blood gas,haemoglobin level, total protein, serum albumin, coagula-
tion profile, calcium, phosphorous, alkaline phosphatase,
vitamin D (25OHD), parathyroid hormone (PTH) and anti-
tissue transglutaminase (tTG) screening tests for coeliac
disease.
At the time of the auxological evaluation, all patients
had a height less than 2 standard deviations (SD) below
the mean for the normal population and/or a subnormal
growth velocity.
In the absence of specific growth charts, age-related
reference values for height, weight, and body mass index
(BMI) were used [14]. As described, height, height vel-
ocity (HV), and BMI were normalised for chronological
age by conversion to standard deviation scores (SDS).
SDS were calculated according to the following formula:
patient value −mean of the age-related reference value/
standard deviation of the age-related reference value [15].
In all subjects, we studied the GH response to GH
stimulation tests (oral clonidine and/or arginine and/or
GH releasing hormone (GHRH) + arginine test).
A GHD diagnosis was made based on auxological cri-
teria (height and/or growth velocity 2 SD below the mean
for the normal population) and a GH peak below 10 μg/L
(below 20 μg/L after the GHRH + arginine test) after two
tests were conducted on two separate occasions [16].
In the event of growth failure with low serum IGF-I and
normal GH concentrations, after pharmacological treat-
ment, assessment of spontaneous 12-hour (12 hr) GH
secretion was performed [17]. In this case, GH profiling at
30-min intervals over 12 hr was performed. GH neurose-
cretory dysfunction (GHNSD) was diagnosed when the
12-hr integrated concentrations of GH were 3.2 μg/litre or
less [17].
Pubertal stage was assessed according to Marshal and
Tanner [18], and testicular volume was determined with
the Prader orchidometer. The age of pubertal onset was
defined as the age at durable Tanner B2 stage for females
and a testicular volume of more than 4 ml for males
(G2). The age at which the onset of puberty occurred
was recorded as the average age between the previous
clinic visit, when the child was still prepubertal, and the
clinic visit when the child was G2/B2. The duration of
puberty was recorded as the time from G2/B2 to G4/B4.
The age at G4/B4 was assessed by averaging the ages at
the previous clinic visit, when the child was G3/B3, and
the clinic visit when the child was G4/B4. Pubertal
growth was defined as growth occurring between the
onset of puberty and the FH.
When the onset of puberty occurred, we studied the
luteinizing hormone (LH) and follicle stimulating hor-
mone (FSH) response to gonadotropin releasing hormone
(GnRH) test, estradiol or total testosterone levels, and we
performed in the females a pelvic ultrasound; at onset of
puberty a normal GnRH test was defined as a peak LH
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diol or testosterone levels and/or pelvic ultrasound were
also carried out.
Bone age (BA) was evaluated through radiographs of the
left hand and wrist and then calculated according to the
Greulich and Pyle method [19]. Predicted adult height
(PAH) was determined using BA, calculated according the
Greulich and Pyle method, and height, calculated accord-
ing to the Bayley-Pinneau method [20]. Target height (TH)
was estimated according the method of Hermanussen
and Cole [21] by calculating the midparent height as an
SDS and correcting this by a factor corresponding to
the influence of assortative mating and parent-offspring
correlations.
In these patients, anthropometric data were collected
periodically (near every 6 months to 1 year). Near- and/or
final height (FH) was commonly defined, recognising that
children may continue to grow after achieving this defin-
ition, for patients in whom both the chronological age
(CA) and BA were at least 14 yr for females and 16 yr for
males [15]. Because 9p trisomy patients have been reported
to continue to grow for a long time, the near-adult
height (NAH) was defined for all female and male pa-
tients with a CA of at least 18 and 20 yr, respectively,
with an HV < 1 cm/year for two consecutive years.
Intracranial imaging was obtained by magnetic resonance
imaging (MRI) using precontrast coronal spin echo T1-
weighted images, followed by post-gadolinium T1-weighted
imaging.
The study was approved by the Anna Meyer Children’s
University Hospital ethics committee, and informed con-
sent was obtained from the children’s parents.
Laboratory methods
Glucose, electrolytes, creatinine, venous blood gas, haemo-
globin level, total protein, serum albumin, coagulation pro-
file, calcium, phosphorous, alkaline phosphatase, 25OHD,
and PTH were measured using standard tests.
Free-T4 and uTSH serum levels were determined
by immunometric assays (ImmuliteTM 2000 Third
Generation, DPC Diagnostic Products Corporation,
Los Angeles, CA, USA). The within- and between-run
coefficients of variation were less than 12.5% for uTSH
and less than 7.5% for FT4.
The IgA-tTG antibody testing was performed using
commercially available ELISA kits (The Binding Site
Limited, Birmingham, UK). The ELISA was performed
in duplicate for all of the sera samples, as per the manu-
facturer’s instructions.
The serum total IGF-I levels were measured using a
solid-phase enzyme-labelled chemiluminescent immuno-
metric assay on the Immulite 2000 automated immunoana-
lyser (Siemens Medical Solutions Diagnostics, Los Angeles,
CA, USA) with an inter-assay coefficient of variation of ~4%.Serum GH was analysed by IMMULITE 2000 Growth
Hormone, an automated chemiluminescence enzyme im-
munoassay analyser. The intra-assay and inter-assay vari-
ability coefficients for this kit at the decision limits were
2.5% and 3.8%, respectively.
LH, FSH, cortisol, estradiol and total testosterone
were measured by a chemiluminescent immunometric
assay (Immulite 2000, Third Generation, DPC Diagnostic
Products Corporation, Los Angeles, CA, USA). The
intra-assay and inter-assay variability coefficients for this
kit at the decision limits were 3.6%, 2.1%, 4.8%, 6.4% and
5.8% respectively.
Chromosome analysis
For the diagnosis of 9p trisomy, chromosome analysis
using GTG-banding was performed according to standard
procedures [22]. A total of 20 metaphases from stimulated
peripheral blood cultures were analysed. Karyotypes were
described according to the International System for
Human Cytogenetic Nomenclature [23].
Fluorescence in situ hybridisation (FISH) was performed
according to the manufacturer’s instructions using a locus
specific probe LSI 9p21, a subtelomeric (ST) probe for the
short arm of chromosome 9 and a chromosome enumer-
ation probe (CEP) 9 (Abbott Molecular/Vysis, USA).
When possible, CGH array analysis was performed
using the Agilent Human Genome CGH Microarray Kit
44 K (Agilent Technologies, Santa Clara, California, USA).
This platform is a high-resolution oligonucleotide-based
microarray with a resolution of approximately 150 kb.
Labelling and hybridisation were performed following
the protocols provided by Agilent: 500 ng of purified
DNA from the patient and 500 ng of control purified
DNA of the same sex (Agilent) were double digested
with RsaI and AluI enzymes (Agilent) for 2 h at 37°C,
which resulted in products between 200 bp and 500 bp
in length. Each digested sample was labelled for 2 h,
minimising light exposure, using the Agilent Genomic
DNA Labeling Kit, using Cy5-dUTP for the patient
DNA and Cy3-dUTP for the reference DNA. Labelled
products were column purified (Agilent) and prepared
by combining the test and control samples according to
the Agilent protocol. After probe denaturation and pre-
annealing with 50 μg of human Cot-1 DNA (Invitrogen),
hybridisation was performed at 65°C for 24 h in a rotat-
ing oven at 20 rpm. After two washing steps, the array
slide was scanned with the Agilent C Scanner. The spot
intensities were measured, and the image files were
quantified using the Agilent Feature Extraction 10.5
software. Text outputs from the quantitative analyses
were imported into Genomic Workbench Standard
Edition 5.0 software (Agilent Technologies). Breakpoint
positions were reported according to Hg 18, build 36
[24,25].
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The main characteristics of our study are reported in
Tables 1 and 2. Three patients were followed-up from
the age of 9p trisomy diagnosis until their final or near
final height (FH). One patient was followed-up for two
years after the GHD diagnosis.
The family history was unremarkable for all of the
subjects in this study. Three patients were only children
of healthy non-consanguineous Italian parents. One
female, the second child, had an older sister with coeliac
disease. None of the parents had short stature or a posi-
tive history for pubertal delay, except for the mother of
patient 1, whose menarche was at the age of 14. The tar-
get height was normal in all families, ranging from 0.1
SDS and −1.2 SDS.Table 1 General, auxological and endocrinological characteris
Main
characteristics
Case 1
Sex (Female: Male) F
Parental age, yrs^
(Mother: Father)
25:26
Target height, cm
(SDS)
162.6 (0.1 SDS)
Gestation (weeks) uncomplicated (41) un
Birth-weight, gr
(SDS)
2.650 (−2.4)
Birth-length, cm
(SDS)
45 (−3.2)
OFC, cm (SDS) 34 (−0.5)
Neuromotor
development
Delayed M
9p trisomy diagnosis At birth
Chromosomal study 47,XX, t (9; 14) (q12; p11.1), +der (9)t(9;14)
(q12; p11.1) [24]
46,
Postnatal growth
delay
Yes
GH stimulation tests
(type)*
(C) - (A)
Basal GH level
(ng/mL)
0.9 - 1.3
Peak GH level
(ng/mL)
7.0 - 7.4
GH axis dysfunction
type
GHD
GH treatment (Y:N) Yes
Puberty onset, B2 or
G2 (yrs)
11.2
B3 or G3 11.9
B4 or G4 12.9
Final height, cm
(SDS)
156.9 (−0.9 SDS).
OFC: Occipito-Frontal head Circumference; GH: Growth Hormone; GHD: Growth Hor
* (A) = arginine; (C) = clonidine; (GA) = GHRH + arginine; ^At conception.There was no apparent parental age effect (Table 1).
All patients were born at term following uncomplicated
gestations. The patients had a low birth-weight (from
−1.2 to −2.4 SDS), birth length (from −1.1 to −3.2 SDS),
and head circumference (from −0.5 to −1.6 SDS).
The facial gestalt in our 9p trisomy syndrome was
striking. Typically, all patients showed significant cranio-
facial characteristics, such as brachycephaly, hypertelor-
ism, down-slanting palpebral fissures, a prominent nose
with a globous tip, a wide philtrum, large low-set ears,
and a short and broad neck (Figure 1). In addition, two
patients experienced frequent infections of the upper air-
ways, bronchitis, and bronchiolitis. Three patients exhib-
ited kyphoscoliosis; of these patients, one also exhibited
spondylolisthesis.tics of our patients
Case 2 Case 3 Case 4
F M F
33:36 25:28 34:36
159 (−0.5 SDS). 166.8 (− 1.2 SDS) 159.5 (−0.5 SDS)
complicated (40) uncomplicated (40) uncomplicated
(39.4)
2.850 (−1.6) 3.140 (0.3 SDS) 2.370 (−1.6 SDS)
46 (−2.4) 49 (−0.4 SDS) 45 (−2.4 SDS)
- 33 (−1.1 SDS). 32 (−1.6 SDS)
oderately delayed Delayed Delayed
7 months 3 years 9 months 2 years 2 months
XX,-9, dup (9) (p12;
p22) [24]
46,XY, der (22)t(9;22)(p21;
p12). [24]
46,XX, dup(9)(p24.3-
p13.3)
Yes Yes Yes
(A) - (C) (GA) - (C) (C) - (GA)
1.7 - 0.2 0.7 - 1.1 0.4 - 0.5
5.0 – 13.0 6.3 – 4.3 9.6 – 8.8
GHNSD GHD GHD
Yes No No
14.5 14.8 -
15.6 16.2 -
16.9 17.5 -
154.4 (−1.3 SDS) 157.5 (−2.6 SDS) -
mone Deficiency; GHNSD: Growth Hormone Neurosecretory Dysfunction.
Table 2 Comparison of our patients’ phenotypes with those reported in the literature
Phenotype Literature (%) Case 1 Case 2 Case 3 Case 4
Downturned oral commissures 95% + + + +
Bulbous nose 95% + + + +
Malformed/low-set ears 70-80% + + + +
Strabismus 70-80% + -
Short philtrum 70-80% + + + +
Hypertelorism 70-80% + + + -
Microcephaly 70-75% - - + -
Brachycephaly 70-75% + + + -
Cleft lip/palate 5% - - - -
Enophthalmos 60-70% + - - -
Ogival palate 60-70% ND + + -
Down-slanting palpebral fissures 60-70% + + + +
Growth retardation 99% + + + +
Delayed skeletal maturation 99% + + + +
Delayed puberty 70-90% - + + ND
Low birthweight 50-70% + + - -
Clinodactyly 90% + + + +
Brachydactyly 90% + + + -
Nail hypoplasia 70-75% + - + +
Lordosis 60% + + - -
Kyphoscoliosis 60% + + + -
Short neck 60-70% + - + -
Single palmar crease 80-95% + + + -
Single crease of the fifth finger 30-50% + + + -
Mental retardation 60% + + + +
Language delay 90% + + + +
Hypotonia 60-70% + + + -
Agenesis/hypoplasia of the corpus callosum < 30% agenesis hypogenesis agenesis ND
Epilepsy < 30% - + - -
Ventriculomegaly < 30% + - - -
Cerebral hypoplasia < 30% - - - -
Cardiac anomalies 20% - - -
Umbilical hernia rare - - -
Other signs - spondylolisthesis urogenital anomalies
ND: not determined.
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all patients presented with substantial growth retard-
ation at the time of 9p trisomy diagnosis for height
(from −3.0 to −3.8 SDS), whereas the BMI was in the
normal range (from 0.0 to −0.9 SDS). At the time of
diagnosis, bone age, determined by Greulich and Pyle’s
method, was always considerably delayed (from – 1 years
at 2 years and 4 months, to −2 yrs 8 months at 5 years
6 months).Endocrine evaluation revealed normal thyroid func-
tion, TSH and cortisol level. However, tTG was negative
in all patients. Growth hormone stimulation tests re-
vealed a classic GHD in patients 1, 3, and 4. In contrast,
patient 2 was determined to have a GHNSD (Table 1).
The plasma concentrations of IGF-I and IGFBP-3 were
low in all patients for their ages and sexes (from −2.0
to −3.4 SDS, and from −1.9 to −2.8 SDS, respectively).
Patients 3 and 4 were not treated with rhGH as a result
Figure 1 Some typical facial dysmorphisms of trisomy 9p
syndrome. AP of case 1 at 7 years of age. The patient showed facial
dysmorphisms typical of trisomy 9p syndrome, such as
brachycephaly, hypertelorism, down-slanting palpebral fissures,
broad prominent nose, and large low-set ears.
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multiple pituitary hormone insufficiencies.
The MRI disclosed agenesis of the corpus callosum in
patients 1 and 3, whereas patient 2 showed hypoplasia of
the corpus callosum (Table 2). All patients showed nor-
mal hypophysis with respect to size and structure.
The auxological follow-up showed that all rhGH-treated
patients (0.22 mg/kg per week subcutaneously) had a very
good response to the GH therapy (Figure 2a and b), with
an SDS-GV that increased remarkably during therapy,
whereas patients 3 and 4 did not experience significant
catch-up growth (Figure 2c and d). As expected, in rhGH-
treated patients IGF-I (SDS) increased significantly after
12 and 24 months of treatment (1.1 ± 0.8 and 1.3 ± 1.1,
respectively; P < 0.001).
During the rhGH treatment, one patient exhibited a
worsening of scoliosis, which however required only a
medical treatment, whereas the degree of scoliosis was
not changed in another rhGH treated patient or in a
rhGH untreated patient.
Pubertal onset was always delayed, except in the patient
1 (Table 1), possibly due to a different age of the start of
rhGH treatment. The hormonal pattern of the hypophysis-
ovary axis was normal in the three patients who were
evaluated. Endocrine evaluation at the age of onset of pu-
berty revealed a pubertal response of gonadotropins in all
patients, with normal estradiol or testosterone levels. The
follow-up analysis of pubertal development was also
normal in these patients. During follow-up, estradiol or
testosterone levels were in accordance to the pubertal
stages.
The final height was consistent with the target height
for those patients who started rhGH treatment; however,
patient 3 had a final height that was considerably lower
than the target height. The extents of the height re-
sponse and recovery appeared to be related to the earlier
age of start of the rhGH treatment.
Finally, in all patients, diagnoses were made based on
chromosomal studies. Array-CGH analysis was conducted
only for patient 4 and demonstrated a large duplication of
near 34 Mb del 9p24.3-p13.3 (Figure 3). The other three
families refused the array-CGH analysis [26].
Discussion
Since the first description of trisomy 9p in 1970, there
has been a rapidly increasing recognition and reporting
of new cases [3,5]. In these patients, the spectrum of
physical features is remarkably consistent, despite the
varying sizes of the duplicated segments [27]. However,
growth and endocrine function in patients with 9p
trisomy syndrome have been scarcely evaluated [5,13].
Our data confirm that delays in growth and develop-
ment can be important features in many patients with
9p trisomy [1; 27]. Nevertheless, our study showed that
Figure 2 Growth charts of the four patients. A) case 1, B) case 2, C) case 3, and D) case 4. The arrow indicates the age of onset of growth
hormone treatment.
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Figure 3 Molecular karyotyping was performed by array-CGH on the proband’s DNA using an Agilent 44 K array platform with a
resolution of approximately 100 kb. Based on the physical mapping positions of the March 2006 Assembly (NCBI36/hg18) of the UCSC
Genome Browser, this analysis showed a duplication of approximately 34 Mb that involved the 9p24.3-p13.3 region, with the breakpoint falling
between 601,628 bp (first duplicated oligomer) and 34,638,095 bp (last duplicated oligomer).
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both postnatal [27], and prenatal onset.
Our data further confirm that bone maturation was sig-
nificantly delayed in all patients [27] and that many of
them may continue to grow up to the age of 20 and thus
may partially catch up, even if their adult height may be
reduced in comparison with their target height, as was the
case in patient 3, who was not treated with hrGH [28].
Interestingly, our data show that this syndrome may be
associated with neurological abnormalities, such as hypo-
genesis or agenesis of the corpus callosum [1]. In fact, in
two of our patients, we observed agenesis and hypogen-
esis of the corpus callosum, congenital midline cerebral
abnormalities that are frequently observed together with
a GH deficiency or other disorders of the hypothalamic-
pituitary axis [29-31]. Observations of brain malforma-
tions in these patients indicate that a brain MRI should
be routinely considered in subjects with this disorder [1].
Our study strongly suggests that an impairment of the
GH – IGF-I axis appears to be another possible featureof the trisomy 9p syndrome, and these patients should
be tested for GH secretion, particularly patients with
trisomy 9p syndrome with growth delay and midline
cerebral malformations.
The response to GH treatment was good in patients 1
and 2; patient 2 exhibited a normal response to the GH
stimulus tests and a neurosecretory pattern at the border-
line of normality. So, GH treatment could also be consid-
ered to ameliorate the stature prognosis in patients with
trisomy 9p and borderline values for the GH dynamic
tests. Nevertheless, further studies will have to confirm
the characteristics of the GH-IGF-I axis in patients with
trisomy 9p syndrome.
Our study also confirms that patients with trisomy 9p
syndrome show a delayed onset of puberty. In these pa-
tients, gonadotropin, thyroid and adrenal function appear
to be normal. The cause of this disorder is not clear: it
could be a peculiarity of the trisomy 9p syndrome, but it
may also be attributable to the important delay in bone
age, as evidenced in patients 2 and 3. Patient 1 had
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precocious GH treatment, which normalised the bone
age/chronological age ratio. In fact, a delayed onset of
puberty, in the absence of gonadotropin deficiency, is a
possible symptom in late-diagnosed cases of GH deficiency
[32]. Therefore, an undiagnosed GH deficiency may par-
tially explain the pubertal delay in these patients.
Patients with trisomy 9p syndrome also show common
skeletal abnormalities, particularly scoliosis [10,11],
which usually develops during the second decade [27].
GH treatment has been described as a factor that in-
creases the risk of the progression of scoliosis [33], even
if the results of other studies do not permit one to con-
clude that a relation exists between GH treatment and
scoliotic progression [34]. Therefore, children at risk for
scoliosis require close monitoring during GH therapy
[35], as our patients 2 and 3 (who had scoliosis and
vertebral schisis). A worsening of scoliosis in response to
GH treatment was especially apparent in patient 2; how-
ever, this patient was not required the stop GH treat-
ment. Thus, patients with 9p trisomy and GH deficiency
should also be carefully evaluated for this problem.Conclusion
In conclusion, our study shows that GH deficiency or
GHND may be diagnosed frequently, and an impairment
of the GH-IGF-I axis may be another feature of patients
affected by trisomy 9p syndrome, suggesting a possible
cause of their growth and puberty delays. In our rhGH-
treated patients, this therapy turned out to be effective.
However, further studies are necessary to evaluate growth
and puberty patterns in this syndrome.
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consent for publication of individual clinical details.
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